Europe regenerative medicines market is expected to reach USD 13.56 billion by 2023 from USD 5.06 billion in 2018, growing at a CAGR of 21.80% during the forecast period 2018-2023. Regenerative medicines repair, replace or regenerate human cells, tissues, or organs affected due to injury, disease, aging processes, congenital defects, and damage due to trauma. These medicines restore normal functions of cells & tissues. These medicines are available in different types such as genes, somatic cells, stem cells, and other types. Some of these medicines (such as stem cells) have the ability to proliferate, differentiate thereby restore the original structure of cells or tissues or organs. Regenerative medicines are used in varied range of degenerative disorders include cardiovascular, neurodegenerative diseases, dermatology, and orthopedic, among others. Majority of the researchers aim to focus on the development of innovative technologies to provide better regenerative medicines and effective healthcare treatment solutions to patients.
Increasing aging population, growing number of life style disorders (diabetes, obesity), rising advancements in the research & development, increasing number of people suffering from chronic disorders (such as liver diseases, blood disorders), and growing involvement of government to help research institutes for the development of regenerative medicines are driving the growth of regenerative medicines market in Europe. However, presence of uncertain regulatory guidelines and stringent ethical laws to conduct research & developments in tissue engineered products & cell-based products are restraining the growth of regenerative medicines market in Europe.
Europe regenerative medicines market is segmented based on product, therapy, and application. Based on product, the market is further sub-segmented as cell-based products and acellular products. Of these, cell-based products segment is estimated to account for larger share of Europe regenerative medicines market by product in 2018. Further, Cell-based products segment is classified as autologous and allogeneic products. Based on therapy, the market is segmented as cell therapy, gene therapy, tissue engineering, and immunotherapy. Of these, cell therapy is estimated to command the highest share of Europe regenerative medicines market by therapy in 2018.
Based on application, the market is segmented as orthopedic & musculoskeletal spine, dermatology, central nervous system, cardiovascular, oncology, diabetes, and other applications. Among these, orthopedic & musculoskeletal spine is estimated to command the largest share of Europe regenerative medicines market by application in 2018.
On the basis of geographical areas, Europe regenerative medicines market is segmented as U.K., Germany, France, Italy, and Spain.
The key players in regenerative medicines market such as, Vertex Pharmaceuticals Incorporated (U.S.), Acelity L.P. Inc. (U.S.), Celgene Corporation (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), Cytori Therapeutics Inc. (U.S.), Advantagene, Inc. (U.S.), and Mesoblast Ltd. (Australia).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Product
5.2.1 Introduction
5.2.2 Cell-Based Products
5.2.2.1 Autologous Cell-Based Products
5.2.2.2 Allogeneic Cell-Based Products
5.2.3 Acellular Products
5.3 Therapy
5.3.1 Introduction
5.3.2 Cell Therapy
5.3.3 Gene Therapy
5.3.4 Tissue Engineering
5.3.5 Immunotherapy
5.4 Application
5.4.1 Introduction
5.4.2 Orthopedic & Musculoskeletal Spine
5.4.3 Dermatology
5.4.4 Cardiovascular
5.4.5 Central Nervous System
5.4.6 Oncology
5.4.7 Diabetes
5.4.8 Other Applications
6. Geographical Analysis
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Vertex Pharmaceuticals Incorporated (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Acelity L.P. Inc. (U.S.)
8.3 Celgene Corporation (U.S.)
8.4 StemCells, Inc. (U.S.)
8.5 Organogenesis Inc. (U.S.)
8.6 NuVasive, Inc. (U.S.)
8.7 Vericel Corporation (Genzyme) (U.S.)
8.8 Cytori Therapeutics Inc. (U.S.)
8.9 Advantagene, Inc. (U.S.)
8.10 Mesoblast Ltd. (Australia)
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
